Drug resistance
Researchers from the Uniformed Services University of the Health Sciences have conducted a study to identify predictors of response to vagus nerve stimulation (VNS) in patients with drug-resistant epilepsy (DRE). The study, published in Neurosurgical Review, found that individuals with generalized epilepsy demonstrated significantly higher responder rates compared to those
Drug resistance
Researchers from Capital Medical University in Beijing, China have made significant findings in the field of epilepsy treatment, specifically regarding the long-term effectiveness and predictors of vagus nerve stimulation (VNS) in drug-resistant epilepsy (DRE) patients. A study published in Acta Epileptologica revealed that VNS effectively controls seizures, with effectiveness and
College faculty
Researchers at Mugla Sitki Kocman University Faculty of Medicine have reported significant results in the use of vagus nerve stimulation (VNS) as a treatment for drug-resistant epilepsy (DRE). The study, which included 40 patients, found that VNS implantation led to a more than 50% reduction in epileptic seizures in 62.
Drug resistance
Research has made significant strides in understanding the therapeutic potential of deep brain stimulation (DBS) in treating drug-resistant epilepsy (DRE). A review conducted by researchers at Iran University of Medical Sciences explores the efficacy of high-frequency stimulation (HFS) and low-frequency stimulation (LFS) in DBS, focusing on mechanisms, target selection, and
Drug resistance
Research has shown that epilepsy is a prevalent neurological disorder affecting more than 50 million individuals worldwide, characterized by seizures and often associated with complications such as cognitive impairments and an increased risk of sudden unexpected death in epilepsy (SUDEP). Despite advancements in pharmacological treatments, one-third of patients develop drug
Cytokines
Research at Monash University has shed new light on the underlying mechanisms of drug-resistant epilepsy (DRE). By comparing plasma inflammatory biomarkers and monocyte phenotypes in patients with DRE and psychogenic non-epileptic seizures (PNES), researchers identified potential therapeutic targets for the development of new treatments. The study, published in Scientific Reports,
Anticonvulsants
A new study published in The Journal of the American Medical Association (JAMA) by Northwell Health clinicians and researchers has found that individuals with newly diagnosed focal epilepsy who have a history of frequent seizures and psychiatric disorders are more likely to be resistant to anti-seizure medications. The study, co-led
Drug resistance
A recent study published in JAMA Neurology has established LITT using the NeuroBlate System as a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The study, conducted by Monteris Medical's 1,000+ patient LAANTERN research initiative, analyzed data from 145 patients across
Drug resistance
Research from the Provincial Hospital suggests that approximately one-third of epilepsy patients suffer from drug-resistant epilepsy (DRE), a condition that poses significant challenges despite the availability of numerous antiepileptic drugs. In response to this issue, researchers have explored alternative approaches to treat DRE, including non-pharmacological methods such as surgery, neurostimulation,
Drug resistance
Researchers at Monteris Medical have announced a groundbreaking study published in JAMA Neurology, highlighting the effectiveness of their NeuroBlate System in treating drug-resistant mesial temporal lobe epilepsy (MTLE). The study, which drew from Monteris' LAANTERN research initiative, involved 145 patients across 15 U.S. institutions and demonstrated long-term seizure
Drug resistance
A landmark study published in JAMA Neurology has provided definitive evidence that the NeuroBlate System is a safe, durable, and minimally invasive surgical option for drug-resistant mesial temporal lobe epilepsy (MTLE). The study, conducted by Monteris Medical, drew from the company's 1,000+ patient LAANTERN research initiative and
Drug resistance
NeuroBlate, a minimally invasive laser interstitial thermal therapy (LITT) system, has been proven effective in treating drug-resistant epilepsy, according to a landmark study published in JAMA Neurology. The study, which analyzed data from 145 patients across 15 U.S. institutions, demonstrates that LITT using NeuroBlate is a safe, durable, and
